20
Cambrex Profarmaco Milano Srl, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Cambrex is an innovative life sciences company with a refreshingly human approach.
One of their notable products is CLORAZEPATE DIPOTASSIUM, with a corresponding US DMF Number 4240.
Remarkably, this DMF maintains an Active status since its submission on June 26, 1981, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of September 27, 2018, and payment made on September 21, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II